Overview

Noroxymorphon hydrochloride

CAS

52446-24-9

Status

Commercial

Noroxymorphone hydrochloride is a quarterly Naltrexone derivative. It stimulates the μ-receptors of the intestine, which stimulates intestinal peristalsis and thus acts against blockages. The principle of action is a new one, that attacks directly at the cause of the constipation. It is therefore used in the therapy of opiate-related constipation, if the effect of the usual laxatives is not sufficient.

Description

Formula

C16H17NO4 • HCl

Molecular weight

323.77 g/mol

Molecular size

small

Controlled Substance

yes

Precursor

no

Your Contact

Marius Hang

Marius Hang

International Division
Director API Export

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Germany
  • Disclaimer

    The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

    No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.

Complementary Services

Share this page